BL0175 not checked
Shanghai Best-Link Bioscience, LLC
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive BL0175 Injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), and thereafter once on Day 1 of each subsequent 28-day treatment cycle (CnD1). Each treatment cycle is defined as 28 consecutive days. The total dose per administration is 500 mg, administered as bilateral gluteal intramuscular injections at 250 mg per buttock. Treatment will continue until disease…”In the company’s words, NCT07658183 on ClinicalTrials.gov
- Tested for
- Breast Cancer (Locally Advanced or Metastatic), Breast Cancer, Ovarian Cancer, Endometrial Cancer, Postmenopausal Women
- Main trialPhase 2
- “The goal of this clinical trial is to compare the objective response rates (ORR) of different doses of BL0175 in patients with postmenopausal hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. The main questions it aims to answer are: 1. Which dose level of BL0175 demonstrates the optimal ORR? 2. What is the recommended phase 3 dose (RP3D) based on efficacy and safety data across the tested dose levels?”In the company’s words, NCT07658183 on ClinicalTrials.gov
Other drugs for Breast Cancer (Locally Advanced or Metastatic)
- D-0502InventisBio Co., Ltd · Phase 3
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
Coming up1
- 31 Oct 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Oct 2027 | A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer | |
| Phase 1Recruiting | 20 Feb 2026 | A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer | |
| Phase 1Not yet recruiting | 8 May 2026 | A Study of Single Dose of BL0175 in Postmenopausal Women |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026